Topics

AI-driven drug discovery fueled 26 novel FDA therapy approvals in early 2026, delivering breakthrough cancer treatments and first-ever options for rare neurological disorders.

The U.S. Food and Drug Administration (FDA) is rapidly integrating AI into its regulatory processes, aiming to enhance efficiency and reduce review times across all centers.